Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to find out if a new anti-cancer drug, dasatinib
(Sprycel®), previously approved for treatment of some forms of leukemia, will be safe and
helpful in treating patients with hormone-refractory prostate cancer.
This is a research study because the study drug, dasatinib (Sprycel®), has not been evaluated
for safety or effectiveness in patients with hormone-refractory prostate cancer. The drug is
approved by the Food and Drug Administration for treatment of some forms of leukemia; thus,
dasatinib (Sprycel®) is not an investigational drug. It has been given safely to hundreds of
patients already. However its safety and usefulness in this study population (prostate
cancer) is unknown.
Subjects who agree to participate will take 150mg (3 pills) of dasatinib (Sprycel®) daily by
mouth for as long as the drug benefits them. During this time, the subject will periodically
return to the office for blood/urine tests, X-rays, imaging scans, and/or to complete
questionnaires.